Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q1 2024 · 70 positions · Total reported value $1.50B · Top-10 concentration 63.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2024 13F filing, Eversept Partners, LP disclosed 70 equity positions with a combined reported value of $1.50B. The filing implies a focused portfolio: its ten largest positions account for 63.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were NTRA ($162.62M), GSK ($161.71M), QQQ ($145.10M). By sector, the heaviest allocations are Health Care 77.3%, Industrials 4.6%. Versus the prior quarter, allocation shifted toward Health Care (+1.0pp) and away from Consumer Discretionary (-0.6pp), Other (-0.9pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 69% of names.

The largest new positions opened in Q1 2024 were PFE ($30.58M), VTRS ($15.72M), MNKD ($10.83M).

Of the 27 positions fully exited versus the prior quarter, the largest were IMGN ($22.21M), ILMN ($12.06M), A ($5.26M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • PFE PFIZER INC · $30.58M
  • VTRS Viatris Inc · $15.72M
  • MNKD MANNKIND CORP · $10.83M
  • LLY ELI LILLY & CO · $10.02M
  • GH GUARDANT HEALTH INC · $9.27M
  • BKD BROOKDALE SR LIVING INC · $8.72M
  • NVO NOVO-NORDISK A S · $8.00M
  • KPTI KARYOPHARM THERAPEUTICS INC · $7.57M

Fully Exited (vs previous quarter)

  • IMGN IMMUNOGEN INC · prev qtr: $22.21M
  • ILMN ILLUMINA INC · prev qtr: $12.06M
  • A AGILENT TECHNOLOGIES INC · prev qtr: $5.26M
  • BHVN BIOHAVEN LTD · prev qtr: $2.86M
  • AFMD AFFIMED N V · prev qtr: $1.05M

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 77.3%
Other 15.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.78M $162.62M 10.85%
10.85%
Reduce
2 3.77M $161.71M 10.79%
10.79%
Add
3 326.80K $145.10M 9.68%
9.68%
Add
4 420.70K $90.36M 6.03%
6.03%
Add
5 6.03M $85.02M 5.67%
5.67%
Reduce
6 1.82M $78.64M 5.25%
5.25%
Reduce
7 3.13M $74.57M 4.97%
4.97%
Reduce
8 251.13K $57.69M 3.85%
3.85%
Add
9 483.16K $50.73M 3.38%
3.38%
Add
10 607.69K $42.78M 2.85%
2.85%
Add
11 103.82K $34.63M 2.31%
2.31%
Reduce
12 421.35K $34.39M 2.29%
2.29%
Reduce
13 1.10M $30.58M 2.04%
2.04%
New
14 711.12K $29.85M 1.99%
1.99%
Reduce
15 7.98M $27.93M 1.86%
1.86%
Add
16 80.56K $26.23M 1.75%
1.75%
Add
17 54.52K $21.46M 1.43%
1.43%
Reduce
18 175.63K $18.46M 1.23%
1.23%
Reduce
19 376.44K $16.32M 1.09%
1.09%
Add
20 30.30K $15.85M 1.06%
1.06%
Reduce
21 1.32M $15.72M 1.05%
1.05%
New
22 197.33K $13.48M 0.90%
0.90%
Reduce
23 35.53K $12.32M 0.82%
0.82%
Add
24 411.48K $11.90M 0.79%
0.79%
Reduce
25 263.54K $11.16M 0.74%
0.74%
Add
26 2.39M $10.83M 0.72%
0.72%
New
27 40.85K $10.20M 0.68%
0.68%
Hold
28 12.88K $10.02M 0.67%
0.67%
New
29 564.50K $9.31M 0.62%
0.62%
Add
30 449.59K $9.27M 0.62%
0.62%
New
31 1.32M $8.72M 0.58%
0.58%
New
32 353.96K $8.37M 0.56%
0.56%
Reduce
33 255.53K $8.26M 0.55%
0.55%
Add
34 62.34K $8.00M 0.53%
0.53%
New
35 5.02M $7.57M 0.51%
0.51%
New
36 1.43M $7.56M 0.50%
0.50%
Reduce
37 14.39K $7.46M 0.50%
0.50%
Reduce
38 955.62K $7.37M 0.49%
0.49%
New
39 92.79K $7.28M 0.49%
0.49%
Reduce
40 1.43M $7.28M 0.48%
0.48%
Reduce
41 5.99M $7.07M 0.47%
0.47%
Reduce
42 2.33M $6.67M 0.45%
0.45%
Reduce
43 1.18M $6.30M 0.42%
0.42%
Add
44 1.09M $6.17M 0.41%
0.41%
Add
45 396.19K $5.84M 0.39%
0.39%
Reduce
46 389.66K $5.63M 0.38%
0.38%
New
47 6.21M $5.53M 0.37%
0.37%
Add
48 119.48K $5.38M 0.36%
0.36%
Add
49 15.35K $5.16M 0.34%
0.34%
Hold
50 13.63K $4.69M 0.31%
0.31%
Reduce

FAQ

What did Eversept Partners, LP buy in 2024-Q1?

In its 2024-Q1 13F filing, Eversept Partners, LP reported 70 equity positions worth $1.50B in aggregate; its largest disclosed positions were NTRA ($162.62M), GSK ($161.71M), QQQ ($145.10M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.50B of long equity holdings across 70 positions as of 2024-Q1. Top-10 holdings account for 63.3% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →